Cargando…

Study of matrix metalloproteinases and their inhibitors in prostate cancer

BACKGROUND: Extracellular matrix metalloproteases (MMPs) have raised an extraordinary interest in cancer research because of their potential role in basal membrane and extracellular matrix degradation, consequently facilitating tumour invasion and metastases development. METHODS: An immunohistochemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escaff, S, Fernández, J M, González, L O, Suárez, A, González-Reyes, S, González, J M, Vizoso, F J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833257/ https://www.ncbi.nlm.nih.gov/pubmed/20160732 http://dx.doi.org/10.1038/sj.bjc.6605569

Ejemplares similares

Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse
por: González, L O, et al.
Publicado: (2007)

Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer
por: Kubben, F J G M, et al.
Publicado: (2006)

Vascular tube formation on matrix metalloproteinase-1-damaged collagen
por: Varani, J, et al.
Publicado: (2008)

Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma
por: Wallard, M J, et al.
Publicado: (2006)

Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer
por: Damery, S, et al.
Publicado: (2013)

Study of matrix metalloproteinases and their inhibitors in breast cancer
por: Vizoso, F J, et al.
Publicado: (2007)

Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients
por: Hurst, N G, et al.
Publicado: (2007)

Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test
por: Wilson, S, et al.
Publicado: (2012)

MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4
por: Tang, W, et al.
Publicado: (2014)

Dual roles of tumour cells-derived matrix metalloproteinase 2 on brain tumour growth and invasion
por: Yu, Ching-Fang, et al.
Publicado: (2017)

Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
por: Giskeødegård, Guro F, et al.
Publicado: (2015)

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
por: de la Piedra, C, et al.
Publicado: (2013)

Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer
por: Li, J, et al.
Publicado: (2009)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma
por: Lemos-González, Y, et al.
Publicado: (2007)

The interplay of matrix metalloproteinase-8, transforming growth factor-β1 and vascular endothelial growth factor-C cooperatively contributes to the aggressiveness of oral tongue squamous cell carcinoma
por: Åström, Pirjo, et al.
Publicado: (2017)

Nanotechnology and Matrix Metalloproteinases in Cancer Diagnosis and Treatment
por: Gonzalez-Avila, Georgina, et al.
Publicado: (2022)

Changes in circulating microRNA levels associated with prostate cancer
por: Bryant, R J, et al.
Publicado: (2012)

The functional significance of microRNA-145 in prostate cancer
por: Zaman, M S, et al.
Publicado: (2010)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
por: Gonzalez de Castro, D, et al.
Publicado: (2012)

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells
por: Tsaur, I, et al.
Publicado: (2012)

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Huang, Jiaqi, et al.
Publicado: (2016)

Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells
por: Martínez-Campa, C, et al.
Publicado: (2009)

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
por: Alcaraz, A, et al.
Publicado: (2013)

Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer
por: Sørensen, K D, et al.
Publicado: (2013)

Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence
por: Truong, M, et al.
Publicado: (2012)

Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
por: Landers, K A, et al.
Publicado: (2008)

Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer
por: Kuefer, R, et al.
Publicado: (2005)

Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate
por: Elkahwaji, J E, et al.
Publicado: (2009)

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
por: McCall, P, et al.
Publicado: (2008)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

Inhibition of constitutive and cxc-chemokine-induced NF-κB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells
por: Seaton, A, et al.
Publicado: (2009)

Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study
por: Lessard, L, et al.
Publicado: (2005)

DKC1 overexpression associated with prostate cancer progression
por: Sieron, P, et al.
Publicado: (2009)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression
por: McCall, P, et al.
Publicado: (2012)

Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test
por: Otero-Estévez, O, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ikdot1bk8k5nebina3j2gahlh1